Led · Series A · Dec 2025

Ferronova is an Adelaide-based medical technology company developing a super-paramagnetic iron oxide nanoparticle tracer system designed to improve image-guided cancer surgery. The nanoparticles bind to lymph-node cells, allowing surgeons to identify tissue that may harbour metastasised cancer and thereby reduce post-operative recurrence. The company is running a 60-patient, two-year clinical trial on stomach and oesophageal cancers at leading Australian centres, having enrolled 54 patients with completion expected in early 2026. Management plans to extend research to the United States over the next two years as it moves toward regulatory approval and commercial launch. Roughly 1.8 million people are diagnosed with stomach and oesophageal cancers annually, underscoring the market need the firm targets. Ferronova has raised a cumulative $17.5 million in Series A funding, giving it capital to complete trials and pursue commercialisation. Its investor base includes Uniseed/UniSuper, South Australian Venture Capital Fund, Artesian Venture Partners, Renew Pharmaceuticals (UltraGreen.ai), several universities, and health-focused funds. The company’s mission is to enhance surgical precision and improve survival rates in complex, early-stage cancers.

Led · Equity · Oct 2024

Val.Ai is an Adelaide-based startup focused on home energy efficiency. It has launched Greenhouse, a home energy efficiency platform. The launch followed the company securing a $1M funding boost. That funding was provided by the SA Venture Capital Fund. The article does not disclose the financing instrument, prior rounds, or other investors. No operating metrics (revenue or user counts) were reported in the article.

Participated · Series A · Apr 2023

Fivecast develops AI- and ML-powered open-source intelligence software to help defense, intelligence, police, border security and corporate clients collect and analyse publicly available information. Its platform enables targeted collection and risk analysis for use cases such as identifying extremists, terrorists, drug trafficking and organised crime. Born out of collaboration between government agencies and leading research institutions, the company supplies OSINT tools for security and intelligence needs. Fivecast plans to use new funding to accelerate expansion and service contracts in key markets, including Five Eyes nations, and to add capabilities in adjacent areas such as corporate security and financial intelligence. It is expanding its team—hiring tradecraft experts, developers and sales and marketing personnel across four offices—and recently surpassed more than 100 employees globally. The company is led by CEO Dr Brenton Cooper. Fivecast builds Fivecast Insight, a machine-learning and AI platform that creates profiles from open-source data such as social media to surface security threats. The platform ingests image, text and video and uses automation to extract potential threats and present them in a way analysts can quickly understand. Customers include law enforcement, defence and national intelligence agencies, and the product has been used in counter-terrorism, serious and organised crime, and border protection operations in Australia and the USA. Founded two years ago as a spin-out from the Data to Decisions Cooperative Research Centre in Adelaide, Fivecast emphasizes a strong research-driven approach. Its initial backing included funds from AusIndustry’s Accelerating Commercialisation program and support from the South Australian Government. The company recently raised $4 million to help bring its technology to the global market.

Participated · Equity · Dec 2022

BiomeBank is a clinical‑stage biotechnology company that secured world‑first regulatory approval of a donor‑derived microbiome drug product and is commercializing supply of that therapy. The company received a $10 million capital raise to scale its GMP manufacturing and increase global supply. BiomeBank plans to reformulate the approved product into a freeze‑dried, encapsulated oral therapy and to advance drug discovery for defined, cultured "second‑generation" microbiome therapies. Its pipeline includes BB265, a cultured therapy for ulcerative colitis slated to enter the company’s first human clinical trial. BiomeBank leverages a large culture collection of bacterial strains and a platform combining machine learning and microbiology, and has announced research collaborations with the Hudson Institute and RMIT. The company has grown headcount from nine to twenty‑two with further growth forecast for 2023.

Participated · Series B · Nov 2021

Fleet Space Technologies builds a satellite-enabled technology stack for mineral prospecting from orbit, aimed at identifying critical mineral deposits. The company’s tools are positioned to help locate resources such as lithium that are important for battery supply chains. The startup is based in Adelaide, Australia. TechCrunch highlighted the company’s recent financing as notable amid a decline in late-stage space deals. Financial details in the coverage focus on the company’s recent Series D; no operating metrics were reported in the article. The coverage framed Fleet’s offering as strategically important for a future that heavily relies on critical minerals. Fleet Space Technologies develops space-based sensing products, notably its ExoSphere system which has seen commercial uptake in mineral exploration. OneVentures highlighted the company’s recent commercial success with ExoSphere and congratulated team members including Flavia Tata Nardini, Matthew Pearson and Federico Tata Nardini. The company announced a $50 million Series C that, according to the post, more than doubled its valuation. The funding was presented as a Series C equity financing; no further instrument breakdown was provided. The article frames the raise as driven by commercial traction rather than disclosing operating metrics such as revenue or user counts. Additional details such as other participating investors, past rounds, founding year or office location were not included in the post. Fleet Space Technologies designs, builds and operates commercial nanosatellites to provide planet-wide connectivity for IoT devices. The company has six satellites already in orbit and is working toward a constellation of 140 small satellites in Low Earth Orbit. Its proprietary nanosatellite technology targets industrial IoT use cases, with the company pitching large efficiency gains, cost savings and reduced carbon emissions for customers. Fleet positions itself as a commercial operator ready to scale its satellite network and expand global coverage. The company is headquartered in Adelaide, South Australia, and is led by CEO and founder Flavia Tata Nardini. The Series B financing and stated commercial traction underpin Fleet's plan to widen its satellite network and serve remote critical infrastructure. Fleet Space Technologies builds shoe-box-sized nanosatellites that deliver low-cost IoT connectivity to commercial and industrial clients, enabling use cases like tracking construction equipment and monitoring pipelines and other utility infrastructure. The company intends to deploy a globe-spanning constellation of these extremely small satellites to serve markets such as agriculture, forestry and mining, and to complement ground-based networks. Fleet has already launched four nanosatellites to orbit on missions from ISRO, Rocket Lab and SpaceX. Its existing fleet is a small part of the planned constellation, but the startup reports "unprecedented demand" with more than three million compatible devices registered to join the network. The satellites are positioned as a scalable, affordable connective layer for billions of low-power devices forecasted in the IoT market. This funding will support launch of Fleet’s next-generation nanosatellites.